Payment overview · 2025
General Payments
$126,226.02
268 reported records · 19 companies
Healthcare provider profile · identity verified
Paul B Ferguson, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HUNTINGTON, WV · NPI 1447459946
Verified facts
What the public records show
CMS Open Payments records show Paul B Ferguson, MD received $126,226.02 in general payments during 2025 across 268 reported records.
Alexion Pharmaceuticals, Inc. accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ampyra, Mavenclad, Nurtec Odt, Qulipta, Ubrelvy, Vumerity, Vyvgart Hytrulo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ubrelvy by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART HYTRULO as an associated drug or biological on 16156 records involving 4992 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vyvgart Hytrulo by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Vumerity by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mavenclad as an associated drug or biological on 3542 records involving 766 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mavenclad by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ampyra by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54,878.02 | 43.5% | 39 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $29,892.31 | 23.7% | 24 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19,005.51 | 15.1% | 13 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $16,913.99 | 13.4% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $4,711.91 | 3.7% | 107 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $260.74 | 0.2% | 33 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $134.93 | 0.1% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $65.87 | 0.1% | 4 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.58 | 0.1% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$46.87 | 0.0% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $41.59 | 0.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.49 | 0.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $37.42 | 0.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.84 | 0.0% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $22.21 | 0.0% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$21.76 | 0.0% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.51 | 0.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.46 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.01 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $115,612.50 | 33 |
| Food and Beverage | $5,064.74 | 206 |
| Travel and Lodging | $4,288.78 | 25 |
| Consulting Fee | $1,199.00 | 3 |
| Education | $61.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $35,096.93 | 27 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $23,489.80 | 10 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $19,005.51 | 13 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $16,399.99 | 21 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $3,656.72 | 47 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $913.80 | 54 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $761.57 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $648.52 | 42 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $247.89 | 31 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $151.80 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $65.87 | 4 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $61.58 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $61.00 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $40.49 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $37.42 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $12.85 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AMPYRA ampyra |
2025 | Ampyra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Mavenclad mavenclad |
2025 | Mavenclad | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 51 | exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART HYTRULO vyvgart hytrulo |
2025 | Vyvgart Hytrulo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART HYTRULO open payments reported associated product |
CMS Open Payments — General Payments 16156 supporting records · 4992 recipient NPIs · example record 1240416058 |
Vyvgart Hytrulo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Mavenclad open payments reported associated product |
CMS Open Payments — General Payments 3542 supporting records · 766 recipient NPIs · example record 1236867010 |
Mavenclad · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 262 | 78 |
| Gabapentin | Gabapentin | 218 | 55 |
| Baclofen | Baclofen | 159 | 45 |
| Fingolimod | Fingolimod Hcl | 142 | 15 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 128 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 126 | 33 |
| Kesimpta Pen | Ofatumumab | 115 | 14 |
| Clonazepam | Clonazepam | 109 | 24 |
| Methylphenidate Hcl | Methylphenidate Hcl | 105 | 17 |
| Pregabalin | Pregabalin | 105 | 25 |
| Primidone | Primidone | 92 | 20 |
| Amantadine | Amantadine Hcl | 91 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 26 |
| Topiramate | Topiramate | 82 | 27 |
| Dalfampridine Er | Dalfampridine | 77 | 16 |
| Levetiracetam | Levetiracetam | 72 | 16 |
| Modafinil | Modafinil | 69 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 55 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 53 | 11 |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 11 |
| Tecfidera | Dimethyl Fumarate | 51 | suppressed |
| Ubrelvy | Ubrogepant | 51 | 12 |
| Rytary | Carbidopa/Levodopa | 45 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Entacapone | Entacapone | 35 | 12 |
| Lacosamide | Lacosamide | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Copaxone | Glatiramer Acetate | 33 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Vumerity | Diroximel Fumarate | 28 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 27 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 26 | suppressed |
| Rufinamide | Rufinamide | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Teriflunomide | Teriflunomide | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 19 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 19 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 13 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Aubagio | Teriflunomide | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Mavenclad | Cladribine | 12 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Ampyra | Dalfampridine | 11 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vyvgart Hytrulo | Efgartigimod-Hyaluronidas-Qvfc | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $126,226.02 · 268 records | Alexion Pharmaceuticals, Inc. | AMPYRA, BOTOX, BRIUMVI, CREXONT, DAYBUE, Gocovri, INBRIJA, INGREZZA, KESIMPTA, Mavenclad, NUPLAZID, NURTEC ODT, PERCEPT PC BRAINSENSE, QULIPTA, Qelbree, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYVGART, VYVGART HYTRULO, XYWAV, Xeomin | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ampyra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error